Uy, Angela

[["dc.bibliographiccitation.firstpage","1026"],["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Der Chirurg"],["dc.bibliographiccitation.lastpage","1033"],["dc.bibliographiccitation.volume","74"],["dc.contributor.author","Dresing, Klaus"],["dc.contributor.author","Pouwels, Claudia"],["dc.contributor.author","Bonsack, S."],["dc.contributor.author","Oellerich, M."],["dc.contributor.author","Schworer, H."],["dc.contributor.author","Uy, Angela"],["dc.contributor.author","Sturmer, K. M."],["dc.date.accessioned","2018-11-07T10:34:55Z"],["dc.date.available","2018-11-07T10:34:55Z"],["dc.date.issued","2003"],["dc.description.abstract","Background. Trauma and emergency surgeons (S) are in contact with high-risk patients (P) infected with HBV, HCV, and HIV without knowing which P is and which is not infected. The aim of this paper was to analyze routine screening (SCR) in trauma care. Method. Microparticle enzyme immunoassays (MEIA) (Abbott Axym system) were analyzed from routine blood samples: HBsAg (Q), HCV version 3.0, HIV 1/2gO. All positive or uncertain samples were confirmed with ELISA/PCR. Results. From January 2002 to October 2002 a total of 1074 emergency P were examined. The results were available within 50 min after admittance to the emergency room. In 53 of 1074 (4.9%) the MEIA was positive or in threshold margins (LV): HBV 15 P plus 3 LV (9 secured by ELISA/PCR), prevalence (PV) 0.84%. HCV 34 P plus I LV (31 secured with ELISA/PCR), PV 2.9%. HIV 2 P, PV 1.86parts per thousand, 1 in co-infection with HCV, I with HBV. Of 42 infections, 21 were unknown before screening, and in 5 P the S suspected an infection. After screening, nine surgical procedures were changed to safer procedures. Conclusion. MEIA is a good tool for quick SCR of HCV, HBV, and HIV in emergency surgery (ES). When the infection is known the S is more aware to perform only safe procedures during surgery (no touch technique) or to use more protective devices (e.g., fluid shield, double gloves). Our results indicate that surgeons and nurses in ES are exposed four to six times more often to infection with HCV, HBV, and HIV than represented by officially published data. We recommend routine SCR of HBV, HCV, and HIV for all P in ES. Prevention procedures are discussed."],["dc.identifier.doi","10.1007/s00104-003-0741-4"],["dc.identifier.isi","000187002800008"],["dc.identifier.pmid","14605720"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/44981"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0009-4722"],["dc.title","HCV, HBV, and HIV infection: risk for surgeon and staff. Results and consequences of routine screening in emergency patients"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Journal of Clinical Virology"],["dc.bibliographiccitation.volume","36"],["dc.contributor.author","Wietzke-Braun, R."],["dc.contributor.author","Maenhardt, Larissa Bettina"],["dc.contributor.author","Rosenberger, Albert"],["dc.contributor.author","Uy, Angela"],["dc.contributor.author","Ramadori, Giuliano"],["dc.contributor.author","Mihm, Sabine"],["dc.date.accessioned","2018-11-07T09:36:40Z"],["dc.date.available","2018-11-07T09:36:40Z"],["dc.date.issued","2006"],["dc.format.extent","S125"],["dc.identifier.isi","000239067300377"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/32668"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Bv"],["dc.publisher.place","Amsterdam"],["dc.relation.conference","12th International Symposium on Viral Hepatitis and Liver Disease"],["dc.relation.eventlocation","Paris, FRANCE"],["dc.relation.issn","1386-6532"],["dc.title","Serological, clinical, and demographic correlates of the outcome of hepatitis C virus infection"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","152"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Journal of Medical Virology"],["dc.bibliographiccitation.lastpage","158"],["dc.bibliographiccitation.volume","60"],["dc.contributor.author","Grethe, S."],["dc.contributor.author","Gemsa, F."],["dc.contributor.author","Monazahian, M."],["dc.contributor.author","Bohme, I."],["dc.contributor.author","Uy, Angela"],["dc.contributor.author","Thomssen, R."],["dc.date.accessioned","2018-11-07T10:36:39Z"],["dc.date.available","2018-11-07T10:36:39Z"],["dc.date.issued","2000"],["dc.description.abstract","Infection with hepatitis C virus (HCV) is still a serious problem in hemodialysis patients, despite screening of blood products for anti-HCV antibodies. The prevalence of HCV in HD patients is between 15% and 30% in Germany. We report the molecular epidemiology of an HCV outbreak in a hemodialysis unit in 1997 is determined. HCV hypervariable region 1 (HVR1) was amplified from serum samples of 19 patients by polymerase chain reaction (PCR) and sequenced directly. In addition, HCV isolates from 3 of these 19 patients were cloned and sequenced. 14 newly infected patients and two patients, who had been infected for several years had very closely related HCV isolates. Unrelated HCV isolates as well as sequences obtained from an HCV outbreak in a plasmapheresis center were found in different, distantly related branches. These findings provide strong evidence for nosocomial transmission of the virus, despite following strict general hygiene precautions. The production of anti-HCV antibody was delayed significantly or seroconversion did not occur at all during the period of: observation in 8 out of 14 newly infected HCV RNA positive patients. Close-meshed reverse transcription-polymerase chain reaction (RT-PCR) analyses on apparently non infected patients within hemodialysis units and upon admission of new patients is strongly recommended for the early detection and prevention of outbreaks of HCV. J. Med. Virol, 60:152-158, 2000. (C) 2000 Wiley-Liss, Inc."],["dc.identifier.doi","10.1002/(SICI)1096-9071(200002)60:2<152::AID-JMV8>3.0.CO;2-I"],["dc.identifier.isi","000084428300008"],["dc.identifier.pmid","10596014"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/45380"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-liss"],["dc.relation.issn","0146-6615"],["dc.title","Molecular epidemiology of an outbreak of HCV in a hemodialysis unit: Direct sequencing of HCV-HVR1 as an appropriate tool for phylogenetic analysis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1192"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","Transfusion"],["dc.bibliographiccitation.lastpage","1197"],["dc.bibliographiccitation.volume","40"],["dc.contributor.author","Legler, Tobias Joerg"],["dc.contributor.author","Riggert, Joachim"],["dc.contributor.author","Simson, G."],["dc.contributor.author","Wolf, C."],["dc.contributor.author","Humpe, Andreas"],["dc.contributor.author","Munzel, U."],["dc.contributor.author","Uy, Angela"],["dc.contributor.author","Kohler, M."],["dc.contributor.author","Heermann, K. H."],["dc.date.accessioned","2018-11-07T10:01:05Z"],["dc.date.available","2018-11-07T10:01:05Z"],["dc.date.issued","2000"],["dc.description.abstract","BACKGROUND: To allow cost-effective RNA testing with NAT techniques, the national authorities of several countries have planned or already introduced tests of mixed specimens, that is, plasma pools. STUDY DESIGN AND METHODS: High-throughput extraction, amplification, and detection of HCV RNA from individual blood donations were optimized and validated. The feasibility of the method and the frequency of anti-HCV-negative, HCV RNA-positive donations were determined in a prospective study of 27,745 allogeneic and 792 autologous individual donations. RESULTS: The 50- and 95-percent detection limits of the method were determined at 44 IU per mt and 162 IU per mt, respectively (World Health Organization HCV reference material). When 201 HCV RNA-positive sera were taken as a reference, the sensitivity was 97.5 percent. The assay specificity was determined at 99.77 percent. During a 20-month period, two seronegative blood donors tested positive in HCV PCR. The viral load of these donations was 6 x 10(6) and 3 x 10(7) copies per mL, respectively. Thus, the yield of HCV RNA testing in this study was 7.63 per 100,000 screened donations (95% CI, 1.25-22.07). In both PCR-positive donors, seroconversion was found in subsequent blood samples. CONCLUSION: This study compares the feasibility of single-donation HCV RNA screening, with the detection of a relatively high percentage of window-phase donations, to data reported from groups using HCV RNA testing of plasma pools. The relative yield of NAT of individual donations versus minipools should be directly investigated in the near future."],["dc.identifier.doi","10.1046/j.1537-2995.2000.40101192.x"],["dc.identifier.isi","000089844200009"],["dc.identifier.pmid","11061854"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/37942"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Assoc Blood Banks"],["dc.relation.issn","0041-1132"],["dc.title","Testing of individual blood donations for HCV RNA reduces the residual risk of transfusion-transmitted HCV infection"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","597"],["dc.bibliographiccitation.issue","13"],["dc.bibliographiccitation.journal","Klinische Wochenschrift"],["dc.bibliographiccitation.lastpage","602"],["dc.bibliographiccitation.volume","63"],["dc.contributor.author","Bienzle, U."],["dc.contributor.author","Guggenmoos-Holzmann, I."],["dc.contributor.author","Zwingenberger, K."],["dc.contributor.author","Thommsen, R."],["dc.contributor.author","Ritter, K."],["dc.contributor.author","Uy, A."],["dc.contributor.author","Bayer, H."],["dc.contributor.author","Schneider, J."],["dc.contributor.author","Hunsmann, G."],["dc.contributor.author","Coester, C. H."],["dc.contributor.author","Kalden, J. R."],["dc.date.accessioned","2022-10-06T13:27:04Z"],["dc.date.available","2022-10-06T13:27:04Z"],["dc.date.issued","1985"],["dc.identifier.doi","10.1007/BF01733012"],["dc.identifier.pii","BF01733012"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/115242"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-602"],["dc.relation.eissn","1432-1440"],["dc.relation.issn","0023-2173"],["dc.relation.orgunit","Deutsches Primatenzentrum"],["dc.title","Lymphadenopathy and antibodies to HTLV-III in homosexual men"],["dc.title.alternative","Clinical, laboratory and epidemiological features"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dspace.entity.type","Publication"]]